Display Settings:

Format

Send to:

Choose Destination
    Clin Pharmacol Ther. 2008 Jan;83(1):160-6. Epub 2007 Sep 19.

    Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.

    Source

    Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. goetz.matthew@mayo.edu

    Abstract

    Tamoxifen continues to be a standard endocrine therapy for the prevention and treatment of estrogen receptor (ER)-positive breast cancer. Tamoxifen can be considered a classic "pro-drug," requiring metabolic activation to elicit pharmacological activity. CYP2D6 is the rate-limiting enzyme catalyzing the conversion of tamoxifen into metabolites with significantly greater affinity for the ER and greater ability to inhibit cell proliferation. Both genetic and environmental (drug-induced) factors that alter CYP2D6 enzyme activity directly affect the concentrations of the active tamoxifen metabolites and the outcomes of patients receiving adjuvant tamoxifen. The a priori knowledge of the pharmacogenetic variation known to abrogate CYP2D6 enzyme activity may provide a means by which the hormonal therapy of breast cancer can be individualized.

    PMID:
    17882159
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2752373
    Free PMC Article

    Images from this publication.See all images (3) Free text

    Figure 1
    Figure 3
    Figure 2

      Supplemental Content

      Icon for Nature Publishing Group Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk